The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
Daniel de la NavaIker Ausejo-MauleonVirginia LaspideaMarisol Gonzalez-HuarrizAndrea LacalleNoelia CasaresMarta ZalacainLucía MarrodanMarc García-MoureMaria C OchoaAntonio Carlos Tallon-CobosReyes Hernandez-OsunaJavier Marco-SanzLaasya DhandapaniIrati Hervás-CorpiónOren J BecherJavad NazarianSabine MuellerTimothy N PhoenixJasper van der LugtMikel HernaezElizabeth GuruceagaCarl J KoschmannSriram VennetiJoshua E AllenMatthew D DunJuan FueyoCandelaria Gomez-ManzanoJaime Gállego Pérez-LarrayaAna Patiño-GarcíaSara LabianoMarta Marija AlonsoPublished in: Neuro-oncology (2024)
The Delta-24-RGD/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.